HomeNewsBusinessCompaniesGovt to import 6.8 lakh vials of Amphotericin-B injections in May, June; domestic production ramped up to 2.6 lakh vials

Govt to import 6.8 lakh vials of Amphotericin-B injections in May, June; domestic production ramped up to 2.6 lakh vials

The government said in May 2021, 3,63,000 vials of Amphotericin-B will be imported, thereby resulting in total availability in the country inclusive of the domestic production of 5,26,752 vials.

May 21, 2021 / 15:09 IST
Story continues below Advertisement
As a deadly second wave of COVID-19 continues to ravage India, cases of mucormycosis, a rare life-threatening infection are being reported among COVID-19 patients. (Image: News18 Creative)
As a deadly second wave of COVID-19 continues to ravage India, cases of mucormycosis, a rare life-threatening infection are being reported among COVID-19 patients. (Image: News18 Creative)

Central government which has given permission May 20 to five drug companies to produce antifungal drug Amphotericin-B liposomal injections, on May 21 said it is in the process of importing a total of 6.8 lakh vials of the drug in May and June.

The import is part of all round efforts to ramp up supply and availability of Amphotericin-B liposomal injection critical for treatment of the of Mucormycosis, also called as Black Fungus disease.

Story continues below Advertisement

The production capacity of these companies was extremely limited in the month of April 2021. As a result of the handholding by Government of India, these domestic manufactures will cumulatively produce 1,63,752 vials of Amphotericin-B in May 2021. This will be further ramped up to 2,55,114 vials in the month of June 2021.

Apart from this, efforts are being made for supplementing the domestic availability of this anti-fungal drug through imports.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show